Regeneration and repair of neural tissue using postpartum-derived cells
First Claim
1. A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and one or more cells in an amount effective to treat the neurodegenerative condition, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and
wherein said cells lack production of CD117.
9 Assignments
0 Petitions
Accused Products
Abstract
Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.
-
Citations
7 Claims
-
1. A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and one or more cells in an amount effective to treat the neurodegenerative condition, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and
wherein said cells lack production of CD117. - View Dependent Claims (2, 3, 5, 6)
- wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and
-
4. A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and cells induced in vitro to differentiate into a neural lineage prior to formulation of the composition, wherein the cells prior to differentiation are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing cells isolated from human umbilical cord tissue substantially free of blood, and wherein the cells prior to differentiation have the following characteristics:
-
a) capable of self-renewal and expansion in culture; b) the potential to differentiate into cells of at least a neural phenotype; c) exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and d) lack production of CD117.
-
-
7. A kit for treating a patient having optic nerve damage, the kit comprising a pharmaceutically acceptable carrier, a population of cells and instructions for using the kit in a method of treating the patient, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype;
- wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and
wherein said cells lack production of CD117.
- wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and
Specification